Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, has announced that it has published a new corporate presentation and investor factsheet.

The corporate presentation outlines Aptamer’s strategy, operational progress and financial performance, offering a comprehensive overview of the Group’s growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.

No new material information has been disclosed in either of these publications.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group secures £360,000 contract with top 3 global pharma

    Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Aptamer signs contract with Metir for Cryptosporidium detection binders

    Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

    Aptamer signs therapeutic development deal with Invizius

    Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Aptamer secures contract Eetension with top 5 pharma partner

    Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities.

      Search

      Search